PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.

Gino Kim InPoorva VaidyaAlexandra FilkinsDavid J HermelKevin G KingOmar RagabWilliam W TsengMark SwansonNiels KokotJulie E LangLawrence MenendezBrittney DeClerckGene KimJenny C HuAlicia TerandoHossein JadvarCharité RickerKimberly A MillerDavid H PengAshley Wysong

Published in: Journal of cancer research and clinical oncology (2020)

PD-1 inhibition produces durable responses among patients with advanced or metastatic CSCC. PD-1 inhibition therapy is well tolerated, but patients should be monitored closely for immune-related adverse events, particularly frail or immune-suppressed patients. Further investigation of potential biomarkers to help identify patients who will derive the most benefit from this therapeutic option is needed.

Keyphrases

squamous cell carcinoma
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
small cell lung cancer
stem cells
patient reported outcomes
radiation therapy
smoking cessation
drug induced